12-month outcomes of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in rare CFTR missense variant. // Genetics in Medicine Open. – URL: https://www.sciencedirect.com/science/article/pii/S2949774426009064?dgcid=rss_sd_all
12-month outcomes of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in rare CFTR missense variant. Genetics in Medicine Open. https://www.sciencedirect.com/science/article/pii/S2949774426009064?dgcid=rss_sd_all
“12-month outcomes of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in rare CFTR missense variant.” Genetics in Medicine Open.
@article{article3720,
title = {12-month outcomes of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in rare CFTR missense variant},
journal = {Genetics in Medicine Open},
url = {https://www.sciencedirect.com/science/article/pii/S2949774426009064?dgcid=rss_sd_all}
}
ABSTRACT Generating bioengineered cartilage that recapitulates the depth-dependent phenotype, structure, and function of native articular cartilage remains a challenge. While cartilage is rich in aggrecan and type II collagen, proper...